Wednesday brought a fresh batch of analyst upgrades across various sectors, with pharmaceutical giant AbbVie Inc. (ABBV) earning a bullish call from HSBC and several smaller companies catching upgraded ratings from major Wall Street firms.

Pharmaceutical Giant Gets HSBC Endorsement

HSBC analyst Rajesh Kumar upgraded AbbVie (ABBV) from Hold to Buy and boosted the price target from $225 to $265. The pharmaceutical company's shares closed at $222.99 on Tuesday, meaning the new target suggests roughly 19% upside potential from current levels.

Agriculture Play Gets BMO Boost

BMO Capital analyst Benjamin Mayhew upgraded The Andersons, Inc. (ANDE) from Market Perform to Outperform and raised the price target from $50 to $65. That's a substantial 30% bump in the target price. The agriculture-focused company's shares closed at $49.36 on Tuesday, putting them right at the lower end of what BMO now sees as fair value.

Precious Metals Streaming Company Shines

RBC Capital analyst Josh Wolfson upgraded Wheaton Precious Metals Corp. (WPM) from Sector Perform to Outperform and raised the price target from $115 to $130. The precious metals streaming company saw its shares close at $109.27 on Tuesday, suggesting the analyst sees about 19% upside ahead.

Morgan Stanley Goes Bullish on Two Names

Morgan Stanley had a busy morning with analyst Courtney Yakavonis upgrading Terex Corporation (TEX) from Equal-Weight to Overweight and raising the price target from $47 to $60. The machinery manufacturer's shares closed at $48.91 on Tuesday, barely above the old target and well below the new one.

Meanwhile, Morgan Stanley analyst Benjamin Swinburne upgraded EchoStar Corporation (SATS) from Equal-Weight to Overweight and lifted the price target from $82 to $110. That's a massive 34% increase in the target price. EchoStar shares closed at $93.54 on Tuesday, already trading above the old target but still below the analyst's new bullish outlook.

These upgrades represent analysts changing their minds about companies they cover, moving from neutral or cautious stances to more optimistic views. Whether it's improving fundamentals, better-than-expected execution, or simply stocks that have gotten too cheap, these rating changes signal that at least some corners of Wall Street are seeing opportunities where they previously didn't.